| Cat.No. | Name | Information |
|---|---|---|
| M2030 | Apremilast | Apremilast is a novel, orally available small molecule inhibitor of PDE4 with IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM. |
| M6804 | IBMX | IBMX is a pDE inhibitor (non-selective) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. |
| M2651 | Doxofylline | Doxofylline is a xanthine derivative and a phosphodiesterase (PDE) inhibitor that can be used in asthma-related studies. |
| M2410 | Avanafil | Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs. |
| M2395 | Anagrelide hydrochloride | Anagrelide HCl is a primary thrombocytopenia compound. It has anti-cyclic adenylate phosphodiesterase activity and inhibits platelet aggregation in both humans and animals. Anagrelide works by inhibiting megakaryocytes from maturing into platelets. |
| M2337 | Crisaborole (AN2728) | Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release. Crisaborole (AN-2728) inhibit PDE4 with an IC50 of 0.49 μM. |
| M2286 | Sildenafil citrate | Sildenafil citrate is an agent used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). |
| M1906 | Piclamilast | Piclamilast (RP 73401) is a potent and selective inhibitor of phosphodiesterase (PDE) 4. |
| M1871 | Roflumilast | Roflumilast (APTA-2217; BYK 20869; B9302-107) is a novel and selective, long-acting inhibitor of phosphodiesterase 4 (PDE-4). |
| M1734 | BAY-60-7550 | BAY-60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human). |
| M1728 | GSK256066 | GSK256066 is a selective phosphodiesterase 4 (PDE4)inhibitor with an IC50 of 3.2 pM. *The compound is unstable in solutions, freshly prepared is recommended |
| M56765 | MMPX | MMPX is a potent PDE1 inhibitor. |
| M56764 | T-0156 | T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. |
| M56763 | TPN171 | TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH). |
| M56762 | Mesopram | Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. |
| M56761 | Atizoram | Atizoram (CP-80,633), a cyclic nucleotide phosphodiesterase (PDE4) inhibitor, elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice. |
| M56760 | Lodenafil | Lodenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED). |
| M56759 | PDE12-IN-1 | PDE12-IN-1 is a potent and selective PDE12 inhibitor with a pIC50 value for enzyme inhibition of 9.1. |
| M56758 | (R)-Avanafil | (R)-Avanafil ((R)-TA1790) is a selective PDE5 inhibitor (IC50: 5.2 nM). |
| M56757 | Enpp-1-IN-2 | Enpp-1-IN-2 is a potent ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) inhibitor with IC50 values of 0.26, 0.48 and 2.0 μM evaluated by means of TG-mAMP, pNP-TMP, and ATP assays, respectively. |
| M56756 | Enpp-1-IN-5 | Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). |
| M56755 | K-Ras-PDEδ-IN-1 | K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
